glp 1 ankylosing spondylitis GLP-1 medications are being explored as an alternative for people living with autoimmune conditions like rheumatoid arthritis and spondylitis. Beyond their role in weight and blood sugar management, they may help GLP-1 coverage for ankylosing spondylitis?

Expert consensus suggests considering pharmacotherapy when there is: Significant weight regain from nadir weight BMI 27 kg/m with obesity-related comorbidities or BMI 30 kg/m Absence of anatomical complications requiring surgical revision Adequate adherence to nutritional and behavioral recommendations Patient willingness to engage in long-term pharmacotherapy The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) guidelines emphasize that pharmacologic therapy should complement, not replace, lifestyle interventions and ongoing bariatric surgical follow-up

who found that no statistically significant difference between the two groups

The effects of dose and duration were similar in trials for diabetes

For most people, this is not a willpower problem